Your session is about to expire
← Back to Search
Imaging Techniques for Congenital Heart Disease
Phase 2
Waitlist Available
Led By Luc Mertens, MD
Research Sponsored by The Hospital for Sick Children
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
All patients with tetralogy of Fallot post repair, transposition of great arteries after arterial switch operation, aortic valvulopathy (aortic stenosis and aortic regurgitation), coarctation of the aorta and cardiomyopathy, who are planned to undergo a cardiac MRI will be eligible.
Be younger than 65 years old
Must not have
Need for general anesthesia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1
Awards & highlights
No Placebo-Only Group
Summary
This trial will study how well different techniques measure diastolic function in children with congenital heart disease, in order to better understand and treat the condition.
Who is the study for?
This trial is for children with certain heart conditions like repaired tetralogy of Fallot, transposition of the great arteries post-surgery, aortic valve problems, narrowed aorta, and cardiomyopathy. They must be scheduled for a cardiac MRI and have given informed consent. It's not suitable for those who can't give consent or need general anesthesia.
What is being tested?
The study compares two heart imaging methods: Cardiac MRI and Echocardiography. The goal is to better understand how different parts of the heart work together in kids with congenital or acquired heart diseases by looking at chamber size, muscle mass changes, twisting motions during beats, and scar tissue.
What are the potential side effects?
There are generally no direct side effects from undergoing an MRI or echocardiograph as they are non-invasive imaging techniques. However, there might be discomfort due to the length of time needed to stay still during the procedures.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have a heart condition and am scheduled for a cardiac MRI.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I will need general anesthesia for my procedure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ day 1
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Atrial Volumes
Secondary study objectives
Assess Ventricular Volumes
Myocardial Scarring
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Magnetic Resonance Imaging (MRI)Experimental Treatment2 Interventions
Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
Group II: EchocardiographExperimental Treatment2 Interventions
Subjects with congenital heart disease will undergo an echocardiograph, as well as an MRI.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Resonance Imaging (MRI)
2015
Completed Phase 4
~1800
Find a Location
Who is running the clinical trial?
The Hospital for Sick ChildrenLead Sponsor
711 Previous Clinical Trials
6,958,080 Total Patients Enrolled
Luc Mertens, MDPrincipal InvestigatorThe Hospital for Sick Children
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have a heart condition and am scheduled for a cardiac MRI.I will need general anesthesia for my procedure.
Research Study Groups:
This trial has the following groups:- Group 1: Echocardiograph
- Group 2: Magnetic Resonance Imaging (MRI)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.